PREDNISONE
(pred'ni-sone)
Apo-Prednisone , Deltasone, Meticorten, Orasone, Panasol, Prednicen-M, Sterapred, Winpred 
Classifications: hormones and synthetic substitutes; adrenal corticosteroid; glucocorticoid
Pregnancy Category: C

Availability

1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg tablets; 5 mg/5 mL, 5 mg/mL solution

Actions

Immediate-acting synthetic analog of hydrocortisone. Effect depends on biotransformation to prednisolone, a conversion that may be impaired in patient with liver dysfunction. Less mineralocorticoid activity than hydrocortisone, but sodium retention and potassium depletion can occur.

Therapeutic Effects

Has antiinflammatory properties.

Uses

May be used as a single agent or conjunctively with antineoplastics in cancer therapy; also used in treatment of myasthenia gravis and inflammatory conditions and as an immunosuppressant.

Contraindications

Systemic fungal infections and known hypersensitivity; pregnancy (category C), lactation.

Cautious Use

Patients with infections; nonspecific ulcerative colitis; diverticulitis; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; myasthenia gravis.

Route & Dosage

Antiinflammatory
Adult: PO 5–60 mg/d in single or divided doses
Child: PO 0.1–0.15 mg/kg/d in single or divided doses

Acute Asthma
Child: PO <1 y, 1–2 mg/kg/d times 3–5 d or 10 mg q12h; 1–4 y, 20 mg q12h; 5–13 y, 30 mg q12h; >13 y, 40 mg q12h times 3–5 d

Administration

Oral
Alternate-Day Therapy (ADT) for Patient on Long-Term Therapy

Adverse Effects (1%)

CNS: Euphoria, headache, insomnia, confusion, psychosis. CV: CHF, edema. GI: Nausea, vomiting, peptic ulcer. Musculoskeletal: Muscle weakness, delayed wound healing, muscle wasting, osteoporosis, aseptic necrosis of bone, spontaneous fractures. Endocrine: Cushingoid features, growth suppression in children, carbohydrate intolerance, hyperglycemia. Special Senses: Cataracts. Hematologic: Leukocytosis. Metabolic: Hypokalemia.

Interactions

Drug: barbiturates, phenytoin, rifampin increase steroid metabolism—increased doses of prednisone may be needed; amphotericin B, diuretics increase potassium loss; ambenonium, neostigmine, pyridostigmine may cause severe muscle weakness in patients with myasthenia gravis; may inhibit antibody response to vaccines, toxoids.

Pharmacokinetics

Absorption: Readily absorbed from GI tract. Peak: 1–2 h. Duration: 1–1.5 d. Distribution: Crosses placenta; distributed into breast milk. Metabolism: Metabolized in liver. Elimination: Hypothalamus-pituitary axis suppression: 24–36 h; Excreted in urine. Half-Life: 3.5 h.

Nursing Implications

Assessment & Drug Effects

Patient & Family Education


Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug